查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602208

尿道感染市場：按適應症、治療方法、最終用戶分類 - 全球預測 2025-2030

Urinary Tract Infection Market by Clinical Indication (Cystitis, Pyelonephritis, Urethritis), Treatment (Diagnosis, Therapatics), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年尿道感染市場價值為116.7億美元，預計到2024年將達到124.7億美元，複合年成長率為6.93%，預計到2030年將達到186.7億美元。

尿道感染（尿道結石）市場包括與預防和管理泌尿器官系統感染疾病相關的診斷、治療和設備。解決尿道結石的必要性是因為尿路結石的盛行率很高，尤其是在女性中，頻繁復發對醫療保健提出了重大挑戰。治療範圍從提供初步診斷服務的初級保健到提供先進治療解決方案的專科醫院。最終使用領域包括私人患者、醫療機構和診斷實驗室。影響該市場的主要成長要素包括全球尿道結石負擔的增加、診斷技術的進步、醫療保健意識的提高以及針對性抗生素和免疫療法解決方案的開發。市場正在見證尖端產品開拓帶來的機遇，例如快速就地檢驗套件和個人化醫療方法。公司可以透過投資研發來創新快速診斷技術和非抗生素治療方案來利用這些機會，並可以應對精準醫療日益成長的趨勢。

主要市場統計
基準年[2023] 116.7億美元
預測年份 [2024] 124.7億美元
預測年份 [2030] 186.7億美元
複合年成長率（%） 6.93%

然而，由於抗生素抗藥性，市場面臨限制。抗藥性挑戰了現有治療方法的有效性，並促使需要昂貴且耗時的新藥開拓。此外，針對創新治療方法的嚴格法律規範可能會減緩新解決方案的市場進入速度。為了克服這些障礙，製藥和生物技術公司之間的合作加速抗生素創新並探索自然和替代治療途徑可能是可行的解決方案。特別是，這個市場的技術創新已經成熟，包括開拓抗藥性抗生素市場、探索益生菌作為預防性解決方案，以及遠端監控和管理患者病情的數位醫療應用，都有很大的空間。隨著市場的發展，公司必須優先考慮靈活地適應不斷變化的消費者行為和監管環境，以在動態的醫療保健環境中保持永續成長和競爭優勢。

市場動態：快速發展的尿道感染市場的關鍵市場洞察

供需的動態交互作用正在改變尿道感染市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 糖尿病和腎結石盛行率增加
    • 女性族群尿道結石發生率高
    • 過度使用抗生素和抗藥性增加導致複雜性尿道結石
  • 市場限制因素
    • 尿道感染藥物如Aminoglycosides和Azole的副作用
  • 市場機會
    • 加強新型抗生素、疫苗和設備的研究和開發
    • 提高公眾意識和醫療保健支出
  • 市場挑戰
    • 關於尿道感染的社會恥辱

波特五力：駕馭尿道感染感染市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解尿道感染市場的外部影響

外部宏觀環境因素在塑造尿道感染感染市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解尿道感染市場的競爭格局

尿道感染感染市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣尿道感染市場供應商的績效評估

FPNV 定位矩陣是評估尿道感染市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 糖尿病和腎結石盛行率增加
      • 女性族群尿道感染發生率高
      • 過度使用抗生素和抗藥性增加導致複雜的尿道感染
    • 抑制因素
      • Aminoglycosides和Azole等治療藥物的副作用
    • 機會
      • 加強新型抗生素、疫苗和設備的研究和開發
      • 公眾意識和不斷上漲的醫療費用
    • 任務
      • 關於尿道感染的社會恥辱
  • 市場區隔分析
    • 臨床適應症：需要強大且先進的藥物治療策略來治療腎盂腎炎
    • 最終用戶：隨著遠端醫療和電子健康平台的普及，在改進自我管理解決方案方面取得了最新進展
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境
  • 客戶客製化

第6章依臨床適應症分類的尿道感染市場

  • 膀胱炎
  • 腎盂腎炎
  • 尿道炎

第7章尿道感染治療市場

  • 診斷
  • 治療藥物
    • Aminoglycosides
    • Azole
    • 奎諾酮
    • BETA-內醯胺

第8章尿道感染市場：依最終用戶分類

  • 醫院
  • 自我管理

第9章美洲尿道感染市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太尿道感染市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲尿道感染市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Vivoo 在 CES 2024 上推出家庭數位 UTI 測試
    • NRx Pharmaceuticals 宣布 FDA核准NRX-101 的臨床實驗(IND) 申請，NRX-101 是一種治療複雜尿道感染的藥物
    • 英恆與美國軍方合作開發治療尿道感染的噬菌體

公司名單

  • Dr. Reddys Laboratories Ltd.
  • Sysmex Corporation
  • AstraZeneca PLC
  • URIT Medical Electronic Co., Ltd.
  • Novartis AG
  • Cipla Limited
  • Pfizer Inc.
  • Bayer AG
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Boehringer Ingelheim International GmbH
  • Shionogi & Co., Ltd.
  • Siemens Healthcare AG
  • AbbVie Inc.
  • F. Hoffmann-La Roche AG
  • Sun Pharmaceutical Industries Limited
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline PLC
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson Services, Inc.
  • Almirall, SA
  • Eli Lilly and Company
  • Viatris Inc.
  • Merck & Co. Inc.
  • Novo Nordisk A/S
Product Code: MRR-034B50030335

The Urinary Tract Infection Market was valued at USD 11.67 billion in 2023, expected to reach USD 12.47 billion in 2024, and is projected to grow at a CAGR of 6.93%, to USD 18.67 billion by 2030.

The urinary tract infection (UTI) market encompasses diagnostics, therapeutic treatments, and devices related to the prevention and management of infections affecting the urinary system. The necessity of addressing UTIs arises due to their high prevalence, particularly among women, with frequent recurrences posing a significant healthcare challenge. Applications extend from primary care settings offering initial diagnostic services to specialized hospitals providing advanced treatment solutions. End-use sectors include individual patients, healthcare facilities, and diagnostic laboratories. Key growth factors influencing this market are the increasing burden of UTIs globally, advancements in diagnostic technologies, a rise in healthcare awareness, and the development of targeted antibiotics and immunotherapy solutions. The market is witnessing opportunities from cutting-edge product developments such as rapid point-of-care testing kits and personalized medicine approaches. Companies can capitalize on these opportunities by investing in R&D to innovate rapid diagnostic technologies and non-antibiotic therapeutic options, aligning with the growing trend towards precision healthcare.

KEY MARKET STATISTICS
Base Year [2023] USD 11.67 billion
Estimated Year [2024] USD 12.47 billion
Forecast Year [2030] USD 18.67 billion
CAGR (%) 6.93%

However, the market faces limitations due to antibiotic resistance, which challenges the effectiveness of existing treatments and drives the need for new drug development, which can be expensive and time-consuming. Furthermore, stringent regulatory frameworks for innovative therapies may delay market entry of novel solutions. To overcome these barriers, collaboration between pharmaceutical companies and biotech firms for accelerated antibiotic innovation and exploring natural and alternative medicine avenues can be viable solutions. The market presents significant areas for innovation, particularly in the development of resistance-free antibiotics, exploration of probiotics as preventive solutions, and digital healthcare applications for monitoring and managing patient conditions remotely. As the market is evolving, firms need to prioritize agile practices to adapt to shifting consumer behaviors and regulatory landscapes, ensuring sustained growth and maintaining competitive advantage in a dynamic healthcare environment.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Urinary Tract Infection Market

The Urinary Tract Infection Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing Prevalence of Diabetes and Kidney Stones
    • High Incidences of UTI in Female Population
    • Complicated UTI due to Rise in Excessive Use of Antibiotics and Drug-Resistance
  • Market Restraints
    • Adverse Effects of Urinary Tract Infection Treatment Drugs such as Aminoglycosides and Azoles
  • Market Opportunities
    • Rise in R&D for a Novel Class of Antibiotics, Vaccines, and Devices
    • Increase in Awareness among People and Healthcare Expenditure
  • Market Challenges
    • Social Stigma Concerning Urinary Tract Infections

Porter's Five Forces: A Strategic Tool for Navigating the Urinary Tract Infection Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Urinary Tract Infection Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Urinary Tract Infection Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Urinary Tract Infection Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Urinary Tract Infection Market

A detailed market share analysis in the Urinary Tract Infection Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Urinary Tract Infection Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Urinary Tract Infection Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Urinary Tract Infection Market, highlighting leading vendors and their innovative profiles. These include Dr. Reddys Laboratories Ltd., Sysmex Corporation, AstraZeneca PLC, URIT Medical Electronic Co., Ltd., Novartis AG, Cipla Limited, Pfizer Inc., Bayer AG, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Boehringer Ingelheim International GmbH, Shionogi & Co., Ltd., Siemens Healthcare AG, AbbVie Inc., F. Hoffmann-La Roche AG, Sun Pharmaceutical Industries Limited, Bristol-Myers Squibb Company, GlaxoSmithKline PLC, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Almirall, S.A., Eli Lilly and Company, Viatris Inc., Merck & Co. Inc., and Novo Nordisk A/S.

Market Segmentation & Coverage

This research report categorizes the Urinary Tract Infection Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Clinical Indication, market is studied across Cystitis, Pyelonephritis, and Urethritis.
  • Based on Treatment, market is studied across Diagnosis and Therapatics. The Therapatics is further studied across Aminoglycosides, Azoles, Quinolones, and B-lactam.
  • Based on End User, market is studied across Hospitals and Self-Administered.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Prevalence of Diabetes and Kidney Stones
      • 5.1.1.2. High Incidences of UTI in Female Population
      • 5.1.1.3. Complicated UTI due to Rise in Excessive Use of Antibiotics and Drug-Resistance
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse Effects of Urinary Tract Infection Treatment Drugs such as Aminoglycosides and Azoles
    • 5.1.3. Opportunities
      • 5.1.3.1. Rise in R&D for a Novel Class of Antibiotics, Vaccines, and Devices
      • 5.1.3.2. Increase in Awareness among People and Healthcare Expenditure
    • 5.1.4. Challenges
      • 5.1.4.1. Social Stigma Concerning Urinary Tract Infections
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Clinical Indication: Need for potent and advanced medication strategies for the management of pyelonephritis
    • 5.2.2. End User: Recent advancements to improve self-administration solutions through the proliferation of telemedicine and e-health platforms
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Urinary Tract Infection Market, by Clinical Indication

  • 6.1. Introduction
  • 6.2. Cystitis
  • 6.3. Pyelonephritis
  • 6.4. Urethritis

7. Urinary Tract Infection Market, by Treatment

  • 7.1. Introduction
  • 7.2. Diagnosis
  • 7.3. Therapatics
    • 7.3.1. Aminoglycosides
    • 7.3.2. Azoles
    • 7.3.3. Quinolones
    • 7.3.4. B-lactam

8. Urinary Tract Infection Market, by End User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Self-Administered

9. Americas Urinary Tract Infection Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Urinary Tract Infection Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Urinary Tract Infection Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Vivoo launches at-home digital UTI test at CES 2024
    • 12.3.2. NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections
    • 12.3.3. Intron enters collaboration with the US Army on bacteriophages for urinary tract infections

Companies Mentioned

  • 1. Dr. Reddys Laboratories Ltd.
  • 2. Sysmex Corporation
  • 3. AstraZeneca PLC
  • 4. URIT Medical Electronic Co., Ltd.
  • 5. Novartis AG
  • 6. Cipla Limited
  • 7. Pfizer Inc.
  • 8. Bayer AG
  • 9. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 10. Boehringer Ingelheim International GmbH
  • 11. Shionogi & Co., Ltd.
  • 12. Siemens Healthcare AG
  • 13. AbbVie Inc.
  • 14. F. Hoffmann-La Roche AG
  • 15. Sun Pharmaceutical Industries Limited
  • 16. Bristol-Myers Squibb Company
  • 17. GlaxoSmithKline PLC
  • 18. Teva Pharmaceutical Industries Ltd.
  • 19. Johnson & Johnson Services, Inc.
  • 20. Almirall, S.A.
  • 21. Eli Lilly and Company
  • 22. Viatris Inc.
  • 23. Merck & Co. Inc.
  • 24. Novo Nordisk A/S

LIST OF FIGURES

  • FIGURE 1. URINARY TRACT INFECTION MARKET RESEARCH PROCESS
  • FIGURE 2. URINARY TRACT INFECTION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. URINARY TRACT INFECTION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. URINARY TRACT INFECTION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. URINARY TRACT INFECTION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. URINARY TRACT INFECTION MARKET DYNAMICS
  • TABLE 7. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CYSTITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PYELONEPHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY URETHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AZOLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY QUINOLONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY B-LACTAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY SELF-ADMINISTERED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. URINARY TRACT INFECTION MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. URINARY TRACT INFECTION MARKET, FPNV POSITIONING MATRIX, 2023